10 studies found for:    "Richter syndrome"
Show Display Options
Rank Status Study
1 Unknown  Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Condition: Richter's Syndrome
Intervention: Drug: Ofatumumab
2 Not yet recruiting Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)
Condition: Richter's Transformation
Intervention: Drug: selinexor
3 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Conditions: Richter's Transformation;   Leukemia
Interventions: Drug: Oxaliplatin;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Pegfilgrastim
4 Active, not recruiting Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Richter Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Completed
Has Results
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Condition: Leukemia
Interventions: Drug: Cytarabine;   Drug: Fludarabine;   Drug: Oxaliplatin;   Drug: Rituximab
6 Completed VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Conditions: Leukemia;   Lymphoma
Intervention: Drug: laromustine
7 Active, not recruiting Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Diffuse Well-Differentiated Lymphocytic Lymphoma;   Prolymphocyctic Leukemia;   Richter's Transformation
Intervention: Drug: PCI-32765
8 Unknown  Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia That Did Not Respond to Fludarabine (Closed to Entry as of 10/2006), Chronic Lymphocytic Leukemia With Autoimmune Hemolytic Anemia, or Richter Transformation
Condition: Leukemia
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
9 Not yet recruiting Phase 1 Study Evaluating ZEN003365 in Patients With Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory Acute Myeloid Leukemia
Conditions: Lymphoproliferative Malignancies;   Acute Myeloid Leukemia
Intervention: Drug: ZEN003365
10 Active, not recruiting 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: 5-Azacytidine

Indicates status has not been verified in more than two years